Hemolysis Supplement Strategies to Address Hemolytic Complications of Immune Globulin Infusions: Transfusion: Vol 55, No S2

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.

Tools

Submit an article

Journal Metrics

Subscribe to this journal

Transfusion

Journal list menu

Tools

Follow journal

Transfusion: Volume 55, Issue S2

Special Issue:Hemolysis Supplement Strategies to Address Hemolytic Complications of Immune Globulin Infusions

Download PDFs

DEDICATION

Publication of this supplement is made possible by support provided by the Food and Drug Administration and the Plasma Protein Therapeutics Association (PPTA).

Dedication

LETTER FROM THE EDITORS

Editors' Notes

INTRODUCTION

Hemolytic adverse events with immune globulin products: product factors and patient risks

Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012

PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS

Epidemiology and Risk Factors for IG-related Hemolysis

The role of isoagglutinins in intravenous immunoglobulin–related hemolysis

Intravenous immune globulin–related hemolysis: comparing two different methods for case assessment

Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin

Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

Pathogenesis of Hemolysis

Pathogenesis and mechanisms of antibody-mediated hemolysis

Possible mechanisms for intravenous immunoglobulin–associated hemolysis: clues obtained from review of clinical case reports

The role of inflammation in intravenous immune globulin–mediated hemolysis

PRODUCT RISK FACTORS

Anti-A and Anti-B Haemagglutinins in IG Products

Anti-A and anti-B: what are they and where do they come from?

Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale

Other Product Risk Factors for Hemolysis

Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?

Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease

IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION

Donor plasma and anti-A/anti-B levels

Donor screening reduces the isoagglutinin titer in immunoglobulin products

Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products

Immune Globulin manufacturing and clearance of isoagglutinins

Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products

Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin

Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products

SUMMARY AND FUTURE DIRECTIONS

Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?

Reviewer Acknowledgment

Sign up for email alerts

Tools

More from this Journal